Qualigen Therapeutics Announces First Patient Dosed In The Phase 1a Clinical Trial Of QN-302 For Treatment Of Advanced Or Metastatic Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) has announced the first patient dosing in the Phase 1a clinical trial of QN-302, a potential treatment for advanced or metastatic solid tumors. The trial is being conducted at START Midwest in Grand Rapids, Michigan. QN-302, a G-Quadruplex (G4)-selective transcription inhibitor, was licensed by Qualigen in January 2021 and received Orphan Drug Designation for the treatment of pancreatic cancer. The company expects to provide an update on the trial's safety and preliminary efficacy in the first half of 2024.
November 07, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Qualigen Therapeutics has initiated the Phase 1a clinical trial of QN-302, a potential treatment for advanced or metastatic solid tumors. The company expects to provide an update on the trial's safety and preliminary efficacy in the first half of 2024.
The initiation of the Phase 1a clinical trial of QN-302 represents a significant milestone for Qualigen Therapeutics. If the trial is successful, it could potentially lead to a new treatment option for advanced or metastatic solid tumors, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100